KIDNEY TRANSPLANTATION IN PATIENTS WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (lection)
Abstract
Kidney transplantation (KT) until recent time was considered contraindicated to patients with end stage kidney failure due to atypical hemolytic uremic syndrome (aHUS) because of high risk of recurrence of the underlying disease and graft loss. However, it has now developed new approaches to prevention and treatment aHUS relapse in posttransplantation period, which significantly improved KT results in these patients. This article discusses the principles of risk assessment aHUS relapse after transplantation, the donor organ selection, features of immunosuppressive therapy, prevention and treatment of aHUS episodes in renal transplant recipients.
About the Authors
E. I. Prokopenko
Moscow regional research and clinical institute named after M.F. Vladimirsky
Russian Federation
Russian Federation
Elena I. Prokopenko MD PhD.
Postgraduate Medical Faculty, Department of transplantology, nephrology and artificial organs.
129110 Russia, Moscow, Shchepkin st., 61/2.
A. V. Vatazin
Moscow regional research and clinical institute named after M.F. Vladimirsky
Russian Federation
Russian Federation
Andrey V. Vatazin, MD, PhD, Professor of medicine, DMedSci.
Postgraduate Medical Faculty, Department of transplantology, nephrology and artificial organs.
129110, Moscow, Shchepkin Str., 61/2, building 6.
E. O. Shcherbakova
Moscow regional research and clinical institute named after M.F. Vladimirsky
Russian Federation
Russian Federation
Evgenia O. Shcherbakova MD.
Postgraduate Medical Faculty, Department of transplantology, nephrology and artificial organs.
129110 Russia, Moscow, Shchepkin st., 61/2.
References
1. Constantinescu AR, Bitzan M, Weiss LS et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004;43: 976–982. doi: 10.1053/j.ajkd.2004.02.010
2. Sullivan M, Erlic Z, Hoffmann MM et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010;74:17–26. doi: 10.1111/j.1469-1809.2009.00554.x
3. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. doi: 10.1186/17501172-6-60
4. Zuber J, Fakhouri F, Roumenina LT et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012;8(11):643-657. doi: 10.1038/nrneph.2012.214
5. Davin JC, Buter N, Groothoff J et al. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009;24(9):1757-1760. doi: 10.1007/s00467-009-1188-8
6. Le Quintrec M, Zuber J, Moulin B et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013;13(3):663-675. doi: 10.1111/ajt.12077
7. Davin JC, van de Kar N. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6(4): 171–185. doi: 10.1177/2040620715577613
8. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35(5):421-447. doi: 10.1016/j.nefro.2015.07.005
9. Козловская НЛ, Прокопенко ЕИ, Эмирова ХМ, Серикова СЮ. Клинические рекомендации по диагностике и лечению атипичного гемолитико-уремического синдрома. Нефрология и диализ 2015;17(3): 242-264 [Kozlovskaya NL, Prokopenko EI, Emirova KhM, Serikova SYu. Klinicheskije rekomendacii po diagnostike i lecheniju atipichnogo gemolitiko-uremicheskogo sindroma. Nefrologija I dializ 2015;17(3): 242-264]
10. Ferraris JR, Ramirez JA, Ruiz S et al. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation. Pediatr Nephrol 2002;17(10):809-814. doi: 10.1007/s00467-002-0936-9
11. Zuber J, Le Quintrec M, Morris H et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 2013;27(4):117125. doi: 10.1016/j.trre.2013.07.003
12. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007;18(8): 2392-2400. doi: 10.1681/ASN.2006080811
13. Raedler H, Heeger PS. Complement regulation of T-cell alloimmunity. Curr Opin Organ Transplant 2011;16(1):54-60. doi: 10.1097/MOT.0b013e3283425419
14. Ažukaitis K, Loirat C, Malina M et al. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2014; 29(7):1273-1277. doi: 10.1007/s00467013-2713-3
15. Licht C, Ardissino G, Ariceta G et al. 1.The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 2015;16:207. doi: 10.1186/s12882-015-0195-1
16. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5:1844–1859. doi: 10.2215/CJN.02210310
17. Zuber J, le Quintrec M, Sberro-Soussan R et al. New insights into postrenal transplant hemolytic uremic syndrome. NatRev Nephrol 2011;7:23–35. doi: 10.1038/nrneph.2010.155
18. Venables JP, Strain L, Routledge D et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006;3:e431. doi: 10.1371/journal.pmed.0030431
19. Roumenina LT, Jablonski M, Hue C et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009; 114:2837–2845. doi: 10.1182/blood-2009-01-197640
20. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007;104:240–245. doi: 10.1073/pnas.0603420103
21. Bresin E, Daina E, Noris M et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006;1:88–99. doi: 10.2215/CJN.00050505
22. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008;12: 619–629. doi: 10.1111/j.1399-3046.2008.00910
23. Le Quintrec M, Zuber J, Noel LH et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009;9:1223–1229. doi: 10.1111/j.1600-6143.2009.02586
24. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21:2180–2187. doi: 10.1681/ ASN.2010030315
25. van Werkhoven MB, Damman J, van Dijk MC et al. Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant 2013;13(4): 875-882. doi: 10.1111/ajt.12130
26. Błogowski W, Dołęgowska B, Sałata D et al. Clinical analysis of perioperative complement activity during ischemia/ reperfusion injury following renal transplantation. Clin J Am Soc Nephrol 2012;7(11):1843-1851. doi: 10.2215/CJN.02200312
27. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4(2):481-508. doi: 10.2215/CJN.04800908
28. Lovric S, Kielstein JT, Kayser D et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series. Nephrol Dial Transplant 2011;26(9):3032-3038. doi: 10.1093/ndt/gfq842
29. Noone D, Al-Matrafi J, Tinckam K et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012;12(9):2546-2553. doi: 10.1111/j.1600-6143.2012.04124
30. Le Quintrec M, Lionet A, Kamar N et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008;8(8):1694-1701. doi: 10.1111/j.1600-6143.2008.02297
31. Wilson CH, Brown AL, White SA et al. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011;92(8):e42-43. doi: 10.1097/ TP.0b013e318230c0bd
32. Bruneau S, Neel M, Roumenina LT et al. Loss of DGK induces endothelial cell activation and death independently of complement activation. Blood 2015;125(6):1038-1046. doi: 10.1182/blood-2014-06-579953
33. Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med 2012;41(3 Pt 2):e115-135. doi: 10.1016/j.lpm.2011.11.013
34. Saland JM, Ruggenenti P, Remuzzi G; Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009;20(5):940-949. doi: 10.1681/ASN.2008080906
35. Koskinen AR, Tukiainen E, Arola J et al. Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome. Am J Transplant 2011;11(9):1885-1895. doi: 10.1111/j.1600-6143.2011.03612
36. Saland JM, Shneider BL, Bromberg JS et al. Successful split liver–kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:201–206. doi: 10.2215/CJN.02170508
37. Wilson C, Torpey N, Jaques B et al. Successful simultaneous liver-kidney transplant in an adult with atypical hemo lytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 2011;58(1):109-112. doi: 10.1053/j.ajkd.2011.04.008
38. Tran H, Chaudhuri A, Concepcion W, Grimm PC. Use of eculizumab and plasma exchange in successful combined liverkidney transplantation in a case of atypical HUS associated with complement factor H mutation. Pediatr Nephrol 2014;29(3):477480. doi: 10.1007/s00467-013-2630-5
39. Chatelet V, Fremeaux-Bacchi V, Lobbedez T et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009;9(11):2644-2645. doi: 10.1111/j.16006143.2009.02817
40. Zimmerhackl LB, Hofer J, Cortina G et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010;362(18):1746-1748. doi: 10.1056/NEJMc1001060
41. Weitz M, Amon O, Bassler D et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26(8):1325-1329. doi: 10.1007/s00467-011-1879-9
42. Roman-Ortiz E, Mendizabal Oteiza S, Pinto S et al. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. Pediatr Nephrol 2014;29(1):149-153. doi: 10.1007/s00467-013-2591-8
43. Zuber J, Le Quintrec M, Krid S et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012;12(12):3337-3354. doi: 10.1111/j.16006143.2012.04252
44. Matar D, Naqvi F, Racusen LC et al. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation 2014;98(11):1205-1212. doi: 10.1097/TP.0000000000000200
45. Broeders EN, Stordeur P, Rorive S, Dahan K. A ‘silent’, new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation. BMJ Case Rep 2014 Dec 23;2014. pii: bcr2014207630. doi: 10.1136/bcr-2014-207630
46. Teixeira CI, Mota RG, Afonso BG et al. Use of Eculizumab in atypical hemolytic uremic syndrome after renal transplantation. J Bras Nefrol 2015;37(1):127-130. doi: 10.5935/01012800.20150018
47. Struijk GH, Bouts AH, Rijkers GT et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013;13(3):819-820. doi: 10.1111/ajt.12032
48. Zlamy M, Hofer J, Elias J, Vogel U. Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy. Pediatr Transplant 2012;16(6):E246-250. doi: 10.1111/j.1399-3046.2011.01585.x
49. Прокопенко ЕИ, Мойсюк ЯГ. Профилактика и лечение инфекционных осложнений у реципиентов солидных органов. В: Готье СВ, Мойсюк АГ, ред. Трансплантология. Фармакотерапия без ошибок. Е-ното, М., 2014: 257-380 [Prokopenko EI, Moysyuk Ya.G. Profilaktika i lechenije infektcionny`kh oslozhnenii` u retcipientov solidny`kh organov. V: Got`e SV, Moi`siuk AG, red. Transplantologija. Farmakoterapija bez oshibok. E-noto, M., 2014: 257-380]
Review
For citations:
Prokopenko E.I., Vatazin A.V., Shcherbakova E.O. KIDNEY TRANSPLANTATION IN PATIENTS WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (lection). Nephrology (Saint-Petersburg). 2016;20(6):111-118. (In Russ.)
Views:
1799
Email this article 